A Trial of Norethisterone Acetate and Expectant Management in Treatment of Simple Ovarian Cysts
Primary Purpose
Ovarian Cyst Simple
Status
Not yet recruiting
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
norethisterone acetate
Sponsored by
About this trial
This is an interventional treatment trial for Ovarian Cyst Simple
Eligibility Criteria
Inclusion Criteria:
- women at age 24-49 years old
- women with simple cyst.( with none of the following: solid parts, papillary formations, peritoneal masses, intraabdominal lymph node enlargement or ascites ) .(13)
- from 5 to10cm in diameter.
- functioning cyst.( defined as largest dimension between 2-8 cm in diameter, unilateral, uniloculated, thin-walled, anechogenic and has distal acoustic enhancement )
Exclusion Criteria:
- premenarche
- postmenopause
- current user of Norethisterone acetate.
- those having contraindication from Norethisterone use.
- gynecologic malignancy
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
norethisterone acetate group
expectant managment group
Arm Description
. In the norethisterone acetate group, the women will receive of norethisterone acetate 5 mg twice daily and are counseled about how to take norethisterone acetate and informed of possible side effects. They also receive a diary card for recording norethisterone acetate intake to be returned to the physician on the day of the next visit. An appointment for the women in both groups was scheduled at one month of treatment for the second ultrasonography. If there is no remission occurred another month of Norethisterone acetate will be given .
Outcomes
Primary Outcome Measures
randomized control trial between (norethisterone acetate)and expectant management in Treatment of simple Ovarian Cysts
Women who had a functional ovarian cyst will be informed about the study.They are then allocated to one or other of the treatment groups (norethisterone acetate or expectant management). the women will be returned to the physician on the day of the next visit. An appointment for the women in both groups was scheduled at one month of treatment for the second ultrasonography. cysts are measured on the day that the participants visited gynecologic clinic by transvaginal or transabdominal US who serviced gynecological patients on a regular basis The following definitions of outcomes were used: Remission, the was defined as ultrasonographic examination being unable to detect the ovarian cyst; Persistence as ultrasonographic examination being able to detect the same ovarian cyst with the same size If there is no remission occurred another month of Norethisterone acetate will be given .
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05293574
Brief Title
A Trial of Norethisterone Acetate and Expectant Management in Treatment of Simple Ovarian Cysts
Official Title
Randomized Control Trial Between Norethisterone Acetate and Expectant Management in Treatment of Simple Ovarian Cysts
Study Type
Interventional
2. Study Status
Record Verification Date
March 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
October 1, 2022 (Anticipated)
Primary Completion Date
October 1, 2023 (Anticipated)
Study Completion Date
December 1, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Assiut University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
To compare the effectiveness of (norethisterone acetate) in the treatment of spontaneously occurring simple ovarian cyst detected by ultrasonography compared with expectant management.
Detailed Description
An ovarian cyst is a sac filled with liquid or semiliquid material that arises in an ovary. The number of diagnoses of ovarian cysts has increased with the widespread implementation of regular physical examinations and ultrasonographic technology.
The discovery of an ovarian cyst causes considerable anxiety in women who fears of malignancy, but the majority of ovarian cysts are benign.
These cysts can develop in females at any stage of life, from the neonatal period to postmenopause. Most ovarian cysts, occur during adolescence, which are hormonally active periods of development.
Most are functional in nature and some times resolve without treatment. However, ovarian cysts can herald an underlying malignant process or, possibly, distract the clinician from a more dangerous condition, such as ectopic pregnancy, ovarian torsion, or appendicitis.
When ovarian cysts are large, persistent, painful, or have concerning radiographic or exam findings, surgery may be required, sometimes resulting in removal of the ovary. If a cyst does not resolve after several menstrual cycles, it is unlikely to be a functional cyst, and further workup is indicated.
Early epidemiological studies reported an inverse relationship between use of oral contraceptives (OCs) and surgically confirmed functional cysts . Many previous studies have indicated that the use of Oral Contraceptive pills (OC) is associated with a lower risk of occurrence of functional ovarian cysts. few studies have considered the treatment effect of OC on functional ovarian cysts. In current clinical practice, gynecologists treat functional ovarian cysts with either OC or expectant management alone. Several randomized controlled trials have shown no significant difference in the resolution of functional ovarian cysts treated with OC over expectant management alone Functional ovarian cyst can occur due to estrogen hyperstimulaton and some theories conceoted that progesterone treatment can suppress this cyst .
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ovarian Cyst Simple
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
66 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
norethisterone acetate group
Arm Type
Experimental
Arm Description
. In the norethisterone acetate group, the women will receive of norethisterone acetate 5 mg twice daily and are counseled about how to take norethisterone acetate and informed of possible side effects. They also receive a diary card for recording norethisterone acetate intake to be returned to the physician on the day of the next visit. An appointment for the women in both groups was scheduled at one month of treatment for the second ultrasonography.
If there is no remission occurred another month of Norethisterone acetate will be given .
Arm Title
expectant managment group
Arm Type
No Intervention
Intervention Type
Drug
Intervention Name(s)
norethisterone acetate
Intervention Description
Norethindrone, a progesterone agonist
Primary Outcome Measure Information:
Title
randomized control trial between (norethisterone acetate)and expectant management in Treatment of simple Ovarian Cysts
Description
Women who had a functional ovarian cyst will be informed about the study.They are then allocated to one or other of the treatment groups (norethisterone acetate or expectant management). the women will be returned to the physician on the day of the next visit. An appointment for the women in both groups was scheduled at one month of treatment for the second ultrasonography. cysts are measured on the day that the participants visited gynecologic clinic by transvaginal or transabdominal US who serviced gynecological patients on a regular basis The following definitions of outcomes were used: Remission, the was defined as ultrasonographic examination being unable to detect the ovarian cyst; Persistence as ultrasonographic examination being able to detect the same ovarian cyst with the same size If there is no remission occurred another month of Norethisterone acetate will be given .
Time Frame
baseline
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
24 Years
Maximum Age & Unit of Time
49 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
women at age 24-49 years old
women with simple cyst.( with none of the following: solid parts, papillary formations, peritoneal masses, intraabdominal lymph node enlargement or ascites ) .(13)
from 5 to10cm in diameter.
functioning cyst.( defined as largest dimension between 2-8 cm in diameter, unilateral, uniloculated, thin-walled, anechogenic and has distal acoustic enhancement )
Exclusion Criteria:
premenarche
postmenopause
current user of Norethisterone acetate.
those having contraindication from Norethisterone use.
gynecologic malignancy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
mohamed mostafa swafi, dr
Phone
01069231210
Email
swafi1994@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
alaa eldin abdelhamid, prof.dr
Phone
01222442140
Email
alaaeldinabdelhamid60@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
abobakr alsokary abbas, prof.dr
Organizational Affiliation
assiut
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
A Trial of Norethisterone Acetate and Expectant Management in Treatment of Simple Ovarian Cysts
We'll reach out to this number within 24 hrs